ISOPRENALINE SULPHATE

Product Description

Background info about Isoprenaline Sulphate Isoprenaline sulphate , orisoproterenol sulphate, is amedicationused for the treatment ofbradycardia(slow heart rate),heart block, and rarely forasthma. It is a non-selective adrenoreceptor agonistthat is the isopropylamine analog ofepinephrine(adrenaline). It is used to treatheart blockand episodes ofAdams-Stokes syndromethat are not caused byventricular tachycardiaor fibrillation, in emergencies forcardiac arrestuntil electric shock can be administered, for bronchospasm occurring during anesthesia, and as an adjunct in the treatment ofhypovolemic shock,septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock. Historical Application Historically, isoprenaline sulphate was used to treat asthma via metered aerosol or nebulizing devices; it was also available in sublingual, oral, intravenous, and intramuscular formulations. The U.S. National Asthma Education and Prevention Program Expert Panel recommends against its use as a nebulizer for acute bronchoconstriction. Contraindications Isoprenaline sulphate should not be used in people with tachyarrhythmias, tachycardia or heart block caused by digitalis poisoning, ventricular arrhythmias which require inotropic therapy, or with angina. Adverse effects Adverse effects of isoprenaline sulphate include nervousness, headache, dizziness, nausea, visual blurring, tachycardia, palpitations, angina, Adams-Stokes attacks, pulmonary edema, hypertension, hypotension, ventricular arrhythmias, tachyarrhythmias, difficulty breathing, sweating, mild tremors, weakness, flushing, and pallor. Isoproterenol has been reported to cause insulin resistance leading to diabetic ketoacidosis. Pharmacology The adverse effects of isoprenaline are also related to the drug’s cardiovascular effects. Isoprenaline can producetachycardia(an elevatedheart rate), which predisposes people who take it tocardiac arrhythmias. History of Isoprenaline Sulphate It was first approved in the US in 1947. Between 1963 and 1968 in England, Wales, Scotland, Ireland, Australia, and New Zealand there was an increase in deaths among people using isoprenaline to treat asthma. This was attributed to overdose: the inhalers produced in that area were dispensing five times the dosage dispensed by inhalers produced in the US and Canada, where the deaths were not observed. (Source: Wikipedia) Only GMP materials will be supplied, logistics all according to GDP.